|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2017
12 months to Dec 31, 2017
|
|
|---|---|---|---|---|---|
| Depreciation expense | |||||
| Amortization of patent | |||||
| Operations: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||
| Depreciation and amortization | |||||
| Amortization of debt discount | |||||
| Impairment of intangible assets | |||||
| Non-cash equity-based compensation expense | |||||
| Gain on forgiveness of debt | |||||
| Equity-based payment of interest | |||||
| Change in operating assets and liabilities | |||||
| Inventory | |||||
| Accounts receivable | |||||
| Prepaid expenses and other assets | |||||
| Deferred charges | |||||
| Deferred revenues | |||||
| Operating lease liabilities | |||||
| Accretion operating lease liabilities | |||||
| Royalty obligation | |||||
| Accounts payable and accrued expenses | |||||
| Net cash used in operating activities | |||||
| Investing: | |||||
| Purchase of debt securities | |||||
| Proceeds from disposition of debt securities | |||||
| Purchase of property and equipment | |||||
| Acquisition, net of cash acquired | |||||
| Net cash used in investing activities | |||||
| Financing: | |||||
| Proceeds from issuance of common stock - offerings | |||||
| Placement cost | |||||
| Dividends paid | |||||
| Proceeds from line of credit | |||||
| Proceeds from issuance of preferred stocks | |||||
| Related Party | |||||
| Nonrelated Party | |||||
| Proceeds from exercise of options | |||||
| Proceeds from issuance of convertible notes | |||||
| Principal repayments of notes payable | |||||
| Net cash provided by financing activities | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
| Change in cash and cash equivalents, and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of the year | |||||
| Cash, cash equivalents and restricted cash at end of year | |||||
| Cash paid during the year for: | |||||
| Interest | |||||
| Supplementary disclosure of non-cash financing activities: | |||||
| Preferred stock conversion to common | |||||
| Substitution of royalty payable to convertible note | |||||
| Assets acquiring excluding identifiable intangible assets and goodwill and cash | |||||
| Identifiable intangible assets and goodwill | |||||
| Identifiable intangible assets and goodwill> | |||||
| Liabilities assumed and consideration payable | |||||
| Debt discount | |||||
| Fair value of shares issued pursuant to acquisition | |||||
| Common stock pursuant to extinguishment of debt | |||||
| Substitution of consideration payable to convertible note | |||||
| Right-of-use assets and operating lease liabilities | |||||
| Accrued dividends payable | |||||
Loading...